Valuation : AstraZeneca Pharma India Limited

Market Cap 173B 1.84B 1.58B 1.49B 1.36B 2.54B 2.55B 17.56B 6.81B 88.9B 6.89B 6.74B 286B P/E 2025
186x
P/E 2026 103x
Enterprise Value 170B 1.8B 1.55B 1.46B 1.33B 2.49B 2.5B 17.22B 6.68B 87.17B 6.76B 6.61B 281B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
18.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-0.23%
1 week-2.47%
Current month-0.57%
1 month-14.35%
3 months-19.40%
6 months-19.37%
Current year-23.08%
1 week 6,832.15
Extreme 6832.15
7,100
1 month 6,832.15
Extreme 6832.15
8,254.9
Current year 6,832.15
Extreme 6832.15
9,219.25
1 year 6,832.15
Extreme 6832.15
9,850
3 years 4,050.15
Extreme 4050.15
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Compliance Officer - 23/02/2026
Chief Tech/Sci/R&D Officer - 03/03/2025
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 52 30/09/2024
Director/Board Member - 09/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-2.47%-23.74%+60.09% 1.84B
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -0.86%+0.74%+23.41%+53.11% 368.02B
Weighted average by Cap. -0.96%+0.55%+37.60%+67.00%

Financials

2025 2026
Net sales 17.16B 182M 156M 147M 134M 251M 252M 1.74B 675M 8.81B 683M 668M 28.37B 22.76B 241M 207M 195M 178M 333M 334M 2.31B 895M 11.68B 905M 885M 37.61B
Net income 1.16B 12.26M 10.55M 9.92M 9.07M 16.96M 17.01M 117M 45.51M 594M 46.03M 45.03M 1.91B 1.88B 19.86M 17.09M 16.08M 14.69M 27.48M 27.55M 190M 73.73M 962M 74.58M 72.95M 3.1B
Net Debt -5B -53M -45.61M -42.91M -39.2M -73.33M -73.53M -507M -197M -2.57B -199M -195M -8.27B -3.37B -35.7M -30.72M -28.9M -26.4M -49.39M -49.53M -342M -133M -1.73B -134M -131M -5.57B
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
04/09/26 ₹6,930.80 -0.23% 784
03/09/26 ₹6,946.95 +1.12% 516
02/09/26 ₹6,870.25 -0.82% 646
01/09/26 ₹6,927.10 -0.63% 376
31/08/26 ₹6,970.75 -1.91% 371
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock